175 related articles for article (PubMed ID: 31347981)
1. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
[TBL] [Abstract][Full Text] [Related]
2. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
[TBL] [Abstract][Full Text] [Related]
3. Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned.
Hung A; Lugo A; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):922-926. PubMed ID: 31347978
[TBL] [Abstract][Full Text] [Related]
4. Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries.
Hellems SS; Soni A; Fasching D; Smith BS; McManus DD
J Manag Care Spec Pharm; 2022 Feb; 28(2):244-254. PubMed ID: 35098745
[No Abstract] [Full Text] [Related]
5. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
Park Y; Raza S; George A; Agrawal R; Ko J
J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
[TBL] [Abstract][Full Text] [Related]
7. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
[TBL] [Abstract][Full Text] [Related]
8. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
9. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
10. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
[No Abstract] [Full Text] [Related]
11. Impact of financial medication assistance on medication adherence: a systematic review.
Hung A; Blalock DV; Miller J; McDermott J; Wessler H; Oakes MM; Reed SD; Bosworth HB; Zullig LL
J Manag Care Spec Pharm; 2021 Jul; 27(7):924-935. PubMed ID: 34185554
[No Abstract] [Full Text] [Related]
12. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
13. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
14. A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.
Appukkuttan S; Duchesneau E; Zichlin ML; Bhak RH; Yaldo A; Gharibo M; Babajanyan S; Duh MS
J Manag Care Spec Pharm; 2019 Apr; 25(4):437-446. PubMed ID: 30608008
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the TRICARE Pharmacy Benefit: A Decade of Change.
Lugo AM; Allerman AA; Trice SK
J Manag Care Spec Pharm; 2019 Nov; 25(11):1195-1200. PubMed ID: 31663455
[TBL] [Abstract][Full Text] [Related]
16. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
[TBL] [Abstract][Full Text] [Related]
17. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
18. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
19. A Primer for Managed Care Residents: How to Conduct Research Using Live Medical and Pharmacy Claims Data.
Hung A; Gedey R; Groeneweg M; Jay M
J Manag Care Spec Pharm; 2019 May; 25(5):538-543. PubMed ID: 31039066
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
